Biotage appoints Nomination Committee

A Nomination Committee consisting of members appointed by the three largest shareholders or group of shareholders and the Chairman of the Board of Directors has been formed for Biotage AB in accordance with the principles adopted by the annual general meeting held on 28 April 2022. The Nomination Committee shall, before the Annual General Meeting 2023, prepare proposal for the election of Chairman and other members of the Board of Directors, the election of Chairman of the Annual General Meeting, election of Auditors, the determination of fees and matters pertaining thereto.

The members of the Nominations Committee are:

- Joachim Spetz, Chairman of the Nomination Committee, appointed by Swedbank Robur Fonder
- Hans Christian Bratterud, appointed by ODIN Fonder
- Christoffer Geijer, appointed by SEB Investment Management

Torben Jørgensen, Chairman of the Board of Biotage AB, is an acting member of the Nomination Committee.

Shareholders wishing to submit a proposal to the Nomination Committee may do so by sending email to the Chairman of the Board of Directors of Biotage AB at: <u>info@biotage.com</u>. Proposals should, in order to be timely assessed by the Nomination Committee, be submitted no later than seven weeks in advance of the meeting.

The Annual General Meeting 2023 in Biotage will be held on Thursday, April 27, 2023 at 5:00pm CET in Uppsala. Shareholders who want to have a matter addressed at the Annual General Meeting 2023 must submit such a proposal to the same address as above (subject "Annual General Meeting 2023" for the e-mail and the letter, respectively) seven weeks in advance of the meeting at the latest.

Contacts

Tomas Blomquist, President and CEO Tel: 0705 23 01 63, tomas.blomquist@biotage.com



About Biotage

Biotage is a Global Impact Tech Company committed to solving society's problems. We offer workflow solutions and products to customers in drug discovery and development and diagnostics, analytical testing and water and environmental testing.

Biotage is contributing to sustainable science with the goal to make the world a healthier, greener and cleaner place – HumanKind Unlimited.

Our customers span a broad range of market segments including pharmaceutical, biotech, diagnostic, contract research and contract manufacturers as well as clinical, forensic and academic laboratories in addition to organizations focused on food safety, clean water and environmental sustainability.

Biotage is headquartered in Uppsala in Sweden and employs 497 people worldwide. The Group had sales of 1,232 MSEK in 2021 and our products are sold in more than 80 countries. Biotage's share (BIOT) is listed in the Large Cap segment on the NASDAQ Stockholm. Website: www.biotage.com

Attachments

Biotage appoints Nomination Committee